Hit identification of IKKβ natural product inhibitor

BackgroundThe nuclear factor-κB (NF-κB) proteins are a small group of heterodimeric transcription factors that play an important role in regulating the inflammatory, immune, and apoptotic responses. NF-κB activity is suppressed by association with the inhibitor IκB. Aberrant NF-κB signaling activity has been associated with the development of cancer, chronic inflammatory diseases and auto-immune diseases. The IKK protein complex is comprised of IKKα, IKKβ and NEMO subunits, with IKKβ thought to play the dominant role in modulating NF-κB activity. Therefore, the discovery of new IKKβ inhibitors may offer new therapeutic options for the treatment of cancer and inflammatory diseases.ResultsA structure-based molecular docking approach has been employed to discover novel IKKβ inhibitors from a natural product library of over 90,000 compounds. Preliminary screening of the 12 highest-scoring compounds using a luciferase reporter assay identified 4 promising candidates for further biological study. Among these, the benzoic acid derivative (1) showed the most promising activity at inhibiting IKKβ phosphorylation and TNF-α-induced NF-κB signaling in vitro.ConclusionsIn this study, we have successfully identified a benzoic acid derivative (1) as a novel IKKβ inhibitor via high-throughput molecular docking. Compound 1 was able to inhibit IKKβ phosphorylation activity in vitro, and block IκBα protein degradation and subsequent NF-κB activation in human cells. Further in silico optimization of the compound is currently being conducted in order to generate more potent analogues for biological tests.

[1]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[2]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[3]  Xuliang Jiang,et al.  Crystal structure of inhibitor of κB kinase β (IKKβ) , 2011, Nature.

[4]  J. Strnad,et al.  IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges , 2007 .

[5]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.

[6]  Hui Yang,et al.  Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer. , 2011, Biochimie.

[7]  Y. Furuichi,et al.  A novel small-molecule inhibitor of NF-kappaB signaling. , 2008, Biochemical and biophysical research communications.

[8]  T. Hwang,et al.  Benzoic acid derivatives, acetophenones, and anti-inflammatory constituents from Melicope semecarpifolia. , 2008, Journal of natural products.

[9]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[10]  S. Uwe.  Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. , 2008, Biochemical pharmacology.

[11]  Y. Song,et al.  NF‐κB as a potential molecular target for cancer therapy , 2007 .

[12]  Dik-Lung Ma,et al.  In silico screening of quadruplex-binding ligands. , 2012, Methods.

[13]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[14]  D. Fabbro,et al.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. , 2005, Structure.

[15]  T. Gilmore,et al.  The Rel/NF-κB signal transduction pathway: introduction , 1999, Oncogene.

[16]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[17]  Dik-Lung Ma,et al.  Drug repositioning by structure-based virtual screening. , 2013, Chemical Society reviews.

[18]  Arup K. Ghose,et al.  Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery , 2008 .

[19]  R. Abagyan,et al.  Structure-based discovery of natural-product-like TNF-α inhibitors. , 2010, Angewandte Chemie.

[20]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[21]  M. Karin.  How NF-κB is activated: the role of the IκB kinase (IKK) complex , 1999, Oncogene.

[22]  J. Shaw,et al.  Antrocamphin A, an anti-inflammatory principal from the fruiting body of Taiwanofungus camphoratus , and its mechanisms. , 2010, Journal of agricultural and food chemistry.

[23]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[24]  Dik-Lung Ma,et al.  Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening. , 2012, Biochimie.

[25]  Ruben Abagyan,et al.  A natural product-like inhibitor of NEDD8-activating enzyme. , 2011, Chemical communications.

[26]  P. Bamborough,et al.  Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta). , 2009, Journal of medicinal chemistry.

[27]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[28]  Peter Ertl,et al.  Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries , 2008, J. Chem. Inf. Model..

[29]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[30]  Dik-Lung Ma,et al.  Molecular docking for virtual screening of natural product databases , 2011 .

[31]  P. Bamborough,et al.  3,5-Disubstituted-indole-7-carboxamides: the discovery of a novel series of potent, selective inhibitors of IKK-β. , 2011, Bioorganic & medicinal chemistry letters.

[32]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[33]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[34]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[35]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[36]  S. Spergel,et al.  Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase. , 2009, Bioorganic & medicinal chemistry letters.

[37]  T. Gilmore.  Introduction to NF-κB: players, pathways, perspectives , 2006, Oncogene.

[38]  D. Chan,et al.  Molecular modeling of drug-DNA interactions: virtual screening to structure-based design. , 2011, Biochimie.

[39]  Dik-Lung Ma,et al.  Structure‐Based Repurposing of FDA‐Approved Drugs as TNF‐α Inhibitors , 2011, ChemMedChem.

[40]  D. Chan,et al.  Discovery of a Natural Product-Like c-myc G-Quadruplex DNA Groove-Binder by Molecular Docking , 2012, PloS one.

[41]  Dik-Lung Ma,et al.  Structure-based design of flavone derivatives as c-myc oncogene down-regulators. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  R. Abagyan,et al.  Discovery of a Drug‐Like G‐Quadruplex Binding Ligand by High‐Throughput Docking , 2008, ChemMedChem.

[43]  H. J. Kim,et al.  NF-κB and IKK as therapeutic targets in cancer , 2006, Cell Death and Differentiation.

[44]  Fang Yang,et al.  Identification of natural product fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening. , 2010, Chemical communications.